FDA Updates Foreign Operations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Updates Foreign Operations



Budget issues and changing global markets are prompting FDA to revise its growing network of overseas offices. The agency is shutting down a small operation in Amman, Jordan, while expanding its presence in India. The Amman staff of two will move back to FDA headquarters to oversee the Middle East and North African medical product activities. Meanwhile, serious drug quality issues are prompting FDA to add seven people to its India office to ramp up drug inspections, bringing the total up to 19. And to better explain FDA policies and standards to local officials and manufacturers, FDA is appointing a native of Kashmir, Altaf Ahmed Lal, to head its India operations. Lal has been in the US for more than 30 years, recently at the US embassy in India. He will have to navigate charges from Indian officials and manufacturers of unwarranted US actions against Indian operators, along with complaints from US pharmaceutical companies that Indian patent decisions aim to bolster domestic firms at the expense of foreign manufacturers.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here